Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ...

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were ...

Kicking off this week in Chicago, this year’s American Association for Cancer Research conference will feature presentations ...

Five- and eight-year trial data to be presented at ASCO demonstrate durable survival outcomes with Xtandi (enzalutamide) plus ...

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

Mature overall survival results of the INAVO120 trial were presented in a press conference for the American Society of ...